Leverage Cognitive Data to Improve Sleep-Wakefulness Drug Evaluation, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn the importance of measuring cognition in sleep medicine trials. The featured speaker will share considerations to understand the nature and magnitude of cognitive symptoms that can occur in adults with disorders of sleep or wakefulness. Attendees will see how cognitive tests can be used to better inform decision-making on the safety and efficacy of novel and licensed drugs.

TORONTO, April 1, 2026 /PRNewswire/ -- Disruption to normal sleep/wake cycles, whether by disease, disorders, injuries of the central nervous system (CNS) or by the drugs used to treat these, can result in substantial disability and increased morbidity and mortality.

For clinical development teams, inconsistent terminology and limited alignment between subjective symptoms and objective cognitive data often make it difficult to interpret safety and efficacy findings in sleep and wakefulness trials. This webinar focuses on how cognition can be systematically measured and interpreted to improve clarity in these programs.

Cognitive symptoms are a consistent and important manifestation of disorders characterized by difficulty sleeping or staying awake. The webinar will examine how cognition is assessed using both subjective reports and standardized neuropsychological tests, and how these approaches can be integrated to generate reliable, decision-ready data. It will also address the common but problematic use of overlapping terms such as fatigue, drowsiness, sleepiness and sedation, and explain how clearer definitions improve the interpretation of trial outcomes.

In this webinar, Prof. Paul Maruff will utilize data to provide a framework for understanding the nature and magnitude of cognitive impairment that can occur in sleep medicine drug development. Drawing on data from patients with disrupted sleep–wake cycles, healthy adults administered sedative medicines and healthy adults undergoing sleep restriction, the session will clarify how cognitive changes can be quantified and distinguished from broader sleep-related symptoms. It will also examine how this framework can support endpoint selection, safety monitoring and efficacy evaluation across development phases.

Register for this webinar to learn how wakefulness can be evaluated through cognitive measurement to support safety and efficacy decisions in sleep medicine clinical trials.

Join Paul Maruff, PhD, Chief Innovation Officer, Cogstate, for the live webinar on Wednesday, April 22, 2026, at 4pm EDT (1pm PDT).

For more information, or to register for this event, visit Leverage Cognitive Data to Improve Sleep-Wakefulness Drug Evaluation.

ABOUT XTALKS

Xtalks — The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks